<DOC>
	<DOCNO>NCT00834743</DOCNO>
	<brief_summary>The objective study compare rate extent absorption metformin test formulation Metformin ER 750 mg Tablets versus reference Glucophage® XR 750 mg Tablets fast condition .</brief_summary>
	<brief_title>Metformin ER 750 mg Tablets , Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>Nonsmoking male female minimum age 18 year ( i.e . nonsmoker nontobacco user least 90 day prior prestudy medical screening ) . Body Mass Index ( BMI weight/height² ) great equal 19 kg/m² less equal 30 kg/m² . Availability subject entire study period willingness adhere protocol requirement , evidence sign Informed Consent Form . Normal finding physical examination , 12lead ECG vital sign ( blood pressure 100140/6090 mmHg , heart rate 5099 beats/min , temperature 35.8ºC 37.5ºC ) . Negative drug abuse , nicotine , alcohol , hepatitis Bsurface antigen , hepatitis C HIV , female subject , pregnancy ( serum ßCG ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . Female subject surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Known history hypersensitivity metformin ( e.g . Glucophage® ) and/or relate drug glyburide ( Diaβeta® , Euglucon® ) , tolbutamide ( Orinase® , Apochlorpropamide ) , acetohexamide ( Dimelor® ) , chlorpropamide ( Diabinese® ) glipizide ( Glucotrol® , Glibenese® ) . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurologic , hematological , liver , kidney disease unless judge clinically significant Principal Investigator , medical designate . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant illness last four week prior entry study . Presence significant physical organ abnormality . Any subject history drug abuse . Any psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator , medical designate . Use prescription medication within 14 day precede entry study . Use overthecounter ( OTC ) medication within seven day precede entry study ( except spermicidal/barrier contraceptive product ) . Female subject : use oral contraceptive contraceptive implant ( Such Norplant® ) within 30 day prior drug administration depot injection progestogen drug ( e.g . DeproProvera® ) within one year prior drug administration . Female subject : presence pregnancy lactation . Any subject blood withdrawn within 56 day precede study , take conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Participation clinical trial investigational drug within 30 day precede study . Any subject donate blood within 56 day precede study . Any subject participate plasma donor plasmapheresis program within seven day precede study . Significant recent history asthma ( After 12 year age ) . Any subject recent ( less one year ) history alcohol abuse . Intolerance venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>